🇺🇸 FDA
Patent

US 11712460

Methods of treating chronic disorders with complement inhibitors

granted A61KA61K31/7088A61K31/7105

Quick answer

US patent 11712460 (Methods of treating chronic disorders with complement inhibitors) held by Apellis Pharmaceuticals, Inc. expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/7088, A61K31/7105, A61K38/10, A61K38/12